Q-linea AB (FRA:3F80) Total Equity: kr304.55 Mil (As of Mar. 2026)


FRA:3F80 Q-linea AB FRA:3F80
68 GF Score
Price kr1.52
GF Value kr1.86
! 3 Warning Signs
View Full Analysis

What is Q-linea AB Total Equity?

Q-linea AB FRA:3F80 +1.00% 68 Total Equity is kr304.55 Mil as of Mar. 2026. GuruFocus rates FRA:3F80 with a GF Score™ of 68/100 and a GF Value™ of kr1.86. The stock has 3 warning signs investors should review.

Q-linea AB's total equity for the quarter that ended in Mar. 2026 was kr304.55 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Q-linea AB Total Equity Historical Data

* Premium members only.

The historical data trend for Q-linea AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-linea AB Total Equity Chart

Q-linea AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 430.45 163.19 189.64 -27.46 338.00

Q-linea AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 120.01 129.45 87.45 338.00 304.55
FRA:3F80
68GF Score
Q-linea AB FRA:3F80
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-linea AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Q-linea AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=369.668-31.665
=338.00

Q-linea AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=333.609-29.059
=304.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr304.55 Mil mean?
Q-linea AB (FRA:3F80) has a Total Equity of kr304.55 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Q-linea AB and its competitors.
Is Q-linea AB's Total Equity too high?
Q-linea AB's current Total Equity is kr304.55 Mil. Overall, Q-linea AB has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Total Equity compare to ABT and SYK?
Q-linea AB's Total Equity of kr304.55 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Q-linea AB and its competitors. Q-linea AB's current Total Equity is kr304.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (FRA:3F80) has a current Total Equity of kr304.55 Mil. The stock's GF Value™ is kr1.86, compared to a current price of kr1.52 — trading 18.5% below its estimated fair value. The current Total Equity is kr304.55 Mil. Q-linea AB's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Q-linea AB (FRA:3F80), the current Total Equity is kr304.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Q-linea AB (FRA:3F80) Overvalued in 2026?

Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued. The current stock price of kr1.52 is trading 18.5% below its estimated GF Value™ of kr1.86.

Key valuation signals for FRA:3F80:

  • Total Equity: kr304.55 Mil
  • GF Value™: kr1.86 vs. price of kr1.52 (18.5% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the FRA:3F80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Q-linea AB Business Description

Other Exchanges QLINEA:Sweden
Address Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
68GF Score

Get the complete analysis for FRA:3F80

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.52
Price
kr1.86
GF Value